MYLAN 2035 MYLAN 2035 (Topiramate (sprinkle) 15 mg)
Pill imprint MYLAN 2035 MYLAN 2035 has been identified as Topiramate (sprinkle) 15 mg.
Topiramate is used in the treatment of migraine prevention; seizure prevention; smoking cessation; tourette's syndrome; trigeminal neuralgia (and more), and belongs to the drug class carbonic anhydrase inhibitor anticonvulsants. There is positive evidence of human fetal risk during pregnancy. Topiramate 15 mg is not subject to the Controlled Substances Act.
See also related documents.
Images for MYLAN 2035 MYLAN 2035 (Topiramate (sprinkle) 15 mg)
- Imprint:
-
MYLAN 2035
MYLAN 2035 - Strength:
- 15 mg
- Color:
- Pink
- Shape:
- Capsule-shape
- Availability:
- Prescription only
- Drug Class:
- Carbonic anhydrase inhibitor anticonvulsants
- Pregnancy Category:
- D - Positive evidence of risk
- CSA Schedule:
- N - Not a controlled drug
- Manufacturer:
- Mylan Pharmaceuticals Inc.
More resources
Topiramate (sprinkle) is associated with the treatment of:
Search by Imprint, Shape or Color
Note: All fields are optional. Use the pill finder to identify medications by visual appearance or name. All Rx and OTC drugs in the US are required by the FDA to have an imprint. If your pill has no imprint it could be a vitamin, diet/herbal/energy pill, illicit or foreign drug. More about imprint codes...
